Drug Profile


Alternative Names: PNU 95666; U 95666

Latest Information Update: 15 Nov 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antiparkinsonians; Anxiolytics; Neuroprotectants
  • Mechanism of Action Dopamine D2 receptor agonists; Serotonin 1A receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 15 Nov 2005 Data from preclinical studies have been added to the Parkinson's Disease and Movement Disorders pharmacodynamics section ,
  • 23 Jul 2004 Discontinued - Phase-II for Parkinson's disease in Japan (unspecified route)
  • 23 Jul 2004 Discontinued - Phase-III for Parkinson's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top